Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 2
1961 1
1962 1
1983 1
1995 1
1997 1
1998 1
1999 1
2001 3
2004 1
2006 2
2010 1
2011 2
2012 5
2013 2
2014 1
2015 2
2016 6
2017 5
2018 3
2019 2
2020 5
2021 4
2022 2
2023 6
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Bupropion-induced pancytopenia.
Kim JL, Chercover D, Masoudi H, Foltz L. Kim JL, et al. Among authors: foltz l. BMJ Case Rep. 2024 Nov 26;17(11):e262831. doi: 10.1136/bcr-2024-262831. BMJ Case Rep. 2024. PMID: 39603678
The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.
Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, Coskun T, Hamang MJ, Sindelar DK, Ballman KK, Foltz LA, Muppidi A, Alsina-Fernandez J, Barnard GC, Tang JX, Liu X, Mao X, Siegel R, Sloan JH, Mitchell PJ, Zhang BB, Gimeno RE, Shan B, Wu X. Emmerson PJ, et al. Among authors: foltz la. Nat Med. 2017 Oct;23(10):1215-1219. doi: 10.1038/nm.4393. Epub 2017 Aug 28. Nat Med. 2017. PMID: 28846098
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM. Al-Ali HK, et al. Among authors: foltz l. Br J Haematol. 2020 Jun;189(5):888-903. doi: 10.1111/bjh.16462. Epub 2020 Feb 4. Br J Haematol. 2020. PMID: 32017044 Free article. Clinical Trial.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Hudgens S, Verstovsek S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan D, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AA, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Mesa RA. Hudgens S, et al. Among authors: foltz l. Value Health. 2024 May;27(5):607-613. doi: 10.1016/j.jval.2024.01.014. Epub 2024 Feb 2. Value Health. 2024. PMID: 38311180 Clinical Trial.
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Mesa RA, Hudgens S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins A, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Verstovsek S. Mesa RA, et al. Among authors: foltz l. Cancer Med. 2023 May;12(9):10612-10624. doi: 10.1002/cam4.5799. Epub 2023 Apr 6. Cancer Med. 2023. PMID: 37021939 Free PMC article. Clinical Trial.
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
Mesa RA, Harrison C, Palmer JM, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AC, Leahy MF, Kawashima J, Ro S, Donahue R, Gorsh B, Deheshi S, Verstovsek S. Mesa RA, et al. Among authors: foltz l. Hemasphere. 2023 Oct 24;7(11):e966. doi: 10.1097/HS9.0000000000000966. eCollection 2023 Nov. Hemasphere. 2023. PMID: 37901848 Free PMC article.
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Gupta V, Yacoub A, Mesa RA, Harrison CN, Vannucchi AM, Kiladjian JJ, Deeg HJ, Fazal S, Foltz L, Mattison RJ, Miller CB, Parameswaran V, Brown P, Hernandez C, Wang J, Talpaz M. Gupta V, et al. Among authors: foltz l. Leuk Lymphoma. 2024 Sep;65(9):1314-1324. doi: 10.1080/10428194.2024.2346733. Epub 2024 Jun 5. Leuk Lymphoma. 2024. PMID: 38838026 Clinical Trial.
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation.
Cherniawsky H, Friedmann J, Nicolson H, Dehghan N, Stubbins RJ, Foltz LM, Leitch HA, Sreenivasan GM, Ambler KLS, Nevill TJ, McGinnis E, Wilson L, Beck DB, Chen LYC, Marcon KM. Cherniawsky H, et al. Among authors: foltz lm. Eur J Haematol. 2023 Jun;110(6):633-638. doi: 10.1111/ejh.13944. Epub 2023 Feb 22. Eur J Haematol. 2023. PMID: 36788756 Review.
64 results